close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Secarna Pharmaceuticals GmbH & Co. KG

News headline image
First Subject Dosed in Lipigon’s Phase I Clinical Study with Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceutical’s LNAplus(TM) Technology Platform
From Secarna Pharmaceuticals GmbH & Co. KG
Via AccessWire
News headline image
Secarna Pharmaceuticals' Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
From Secarna Pharmaceuticals GmbH & Co. KG
Via AccessWire
News headline image
Secarna Pharmaceuticals' Partner Denali Therapeutics Exercises Option for LNAplusTM Antisense Oligonucleotide Development Program in Neurodegeneration
From Secarna Pharmaceuticals GmbH & Co. KG
Via AccessWire
News headline image
Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies
From Secarna Pharmaceuticals GmbH & Co. KG
Via AccessWire
Tickers ACHL
News headline image
Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development of Novel ASO Therapeutics in the Field of CNS Diseases
From Secarna Pharmaceuticals GmbH & Co. KG
Via AccessWire
News headline image
Secarna Pharmaceuticals has Initiated a Transnational Scientific Consortium to Identify New Biomarkers for Personalized Cancer Immunotherapy with ASOs
From Secarna Pharmaceuticals GmbH & Co. KG
Via AccessWire
Topics Artificial Intelligence Intellectual Property
News headline image
Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec Expand Strategic Partnership in the Field of Antisense Drug Discovery
From Secarna Pharmaceuticals GmbH & Co. KG
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today